{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-008677","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.286239+00:00","generated_at":"2026-06-17T22:12:21.142206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 Pharma FY2022 net loss $93.9M; WHIM trial success, NDA submission planned for H2 2023","bullets":["Cash $123M as of Dec 31, 2022; funds operations into Q2 2024.","Phase 3 4WHIM trial met primary and key secondary endpoints; NDA submission expected early 2H 2023.","Phase 2 chronic neutropenia trial enrolling; data and regulatory path clarity expected 2Q/3Q 2023.","Gross proceeds ~$120M from two 2022 financings; amended Hercules loan lowered cash covenant to $20M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-008677","json":"https://secwatch.observer/filing/0001628280-23-008677.json","markdown":"https://secwatch.observer/filing/0001628280-23-008677.md","text":"https://secwatch.observer/filing/0001628280-23-008677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/0001628280-23-008677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/xfor-20230321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:12:21.142206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"700ce88c3c396589756416bc4b86174761ea12d9","claim":"X4 Pharmaceuticals, Inc reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 21, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/0001628280-23-008677-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}